Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: One-year durability

Plastic and Reconstructive Surgery

Volumn 118, Issue 3 SUPPL., 2006, Pages

  Silvers, Stacey L ^b   Eviatar, Joseph A ^a   Echavez, Michael I ^b   Pappas, Alexandra L ^b  

^a Chelsea Eye and Cosmetic Surgery Associates   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYAPATITE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECCHYMOSIS; EDEMA; ERYTHEMA; ESTHETICS; FACE; FACE MALFORMATION; FACIES; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PHOTOGRAPHY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PATIENT SAFETY; PATIENT SATISFACTION; PRIORITY JOURNAL; PRURITUS; RATING SCALE; SCORING SYSTEM; SKINFOLD THICKNESS; SOFT TISSUE DEFECT;

ADULT; ANTHROPOMETRY; BIOCOMPATIBLE MATERIALS; CHEEK; COSMETIC TECHNIQUES; DURAPATITE; ECCHYMOSIS; ESTHETICS; FEMALE; FOLLOW-UP STUDIES; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MICROSPHERES; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33748267482     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.prs.0000234847.36020.52     Document Type: Article

References (27)

1. Borderi, M., Verucchi, G., Tadolini, M., et al. Metabolic complications of HIV-1-antiretroviral therapy: The lipodystrophy syndrome. New Microbiol. 24: 303, 2001.
2. Carr, A., Samaras, K., Burton, S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: 51, 1998.
3. Graber, A. Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection. Endocr. Pract. 7: 430, 2001.
4. Jan, V., Cervera, P., Maachi, M., et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir. Ther. 9: 555, 2004.
5. McComsey, G., and Walker, U. A. Role of mitochondria in HIV lipoatrophy: Insight into pathogenesis and potential therapies. Mitochondrion 4: 111, 2004.
6. Milinkovic, A., and Martinez, E. Current perspectives on HIV-associated lipodystrophy syndrome. J. Antimicrob. Chemother. 56: 6, 2005.
7. Cofrancesco, J., Jr., Brown, T., and Martins, C. R. Management options for facial lipoatrophy. AIDS Read. 14: 639, 2004.
8. Tsiodras, S., Mantzoros, C., Hammer, S., and Samore, M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch. Intern. Med. 160: 2050, 2000.
9. Lichtenstein, K. A. Redefining lipodystrophy syndrome: Risks and impact on clinical decision making. J. Acquir. Immune Defic. Syndr. 39: 395, 2005.
10. Lichtenstein, K. A., Delaney, K. M., Armon, C., et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 32: 48, 2003.
11. Galli, M., Veglia, F., Angarano, G., et al. Gender differences in antiviral drug-related adipose tissue alterations: Women are at higher risk than men and develop particular lipodystrophy patterns. J. Acquir. Immune Defic. Syndr. 34: 58, 2003.
12. Martinez, E., Garcia-Viejo, M. A., Blanch, L., and Gatell, J. M. Lipodystrophy syndrome in patients with HIV infection: Quality of life issues. Drug Saf. 24: 157, 2001.
13. Echavez, M., and Horstman, W. Relationship between lipoatrophy and quality of life. AIDS Read. 15: 369, 2005.
14. Roth, J. S. Restorative treatment approaches for HIV-associated lipoatrophy. PRN Notebook 10: 24, 2005.
15. Gooderham, M., and Solish, N. Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy. Dermatol. Surg. 31: 104, 2005.
16. Werschler, W. The aging face and nonsurgical total facial restoration. Cosmet. Dermatol. 19: 3, 2006.
17. Ditre, C. Aesthetic considerations in the treatment of facial lipoatrophy. Cosmet. Dermatol. 19: 9, 2006.
18. Felderman, L. Radiesse for facial rejuvenation. Cosmet. Dermatol. 18: 823, 2005.
19. Laeschke, K. Biocompatibility of microparticles into soft tissue fillers. Semin. Cutan. Med. Surg. 23: 214, 2004.
20. Comite, S. L., Liu, J. F., Balasubramanian, S., and Christian, M. A. Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse). Dermatol. Online J. 10, 2004.
21. Tzikas, T. Evaluation of the Radiance FN soft tissue filler for facial soft tissue augmentation. Arch. Facial Plast. Surg. 6: 234, 2004.
22. Marmur, E. S., Phelps, R., and Goldberg, D. J. Clinical, histologic and electron microscope findings after injection of a calcium hydroxylapatite filler. J. Cosmet. Laser Ther. 6: 223, 2004.
23. Flaharty, P. Radiance. Facial Plast. Surg. 20: 165, 2004.
24. Kanchwala, S. K., Holloway, L., and Bucky, L. P. Reliable soft tissue augmentation: A clinical comparison of injectable soft-tissue fillers for facial-volume augmentation. Ann. Plast. Surg. 55: 30, 2005.
25. Narins, R., Brandt, F., Leyden, J., et al. A randomized, double blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the corrections of nasolabial folds. Dermatol. Surg. 29: 588, 2003.
26. James, J., Carruthers, A., Carruthers, J. HIV-associated facial lipoatrophy. Dermatol. Surg. 28: 979, 2002.
27. Sommer, B., Zschoke, I., Bergeld, D., et al. Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines. Dermatol. Surg. 29: 456, 2003.